ACESION PHARMA ApS: Financial statements 2022
CVR: 34083738
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ACESION PHARMA ApS (CVR 34083738) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -46,780,000 compared with DKK -25,157,000 the year before. Equity in the 2022 report amounted to DKK 22,983,000. The solvency ratio was 43.2%.
- Profit/Loss
- DKK -46,780,000
- Equity
- DKK 22,983,000
- Total Assets
- DKK 53,191,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -46.8 mio. | 23 mio. | - |
| 2021 | 0 | - | -25.2 mio. | 10.3 mio. | - |
| 2020 | 0 | - | -31.4 mio. | -20 mio. | - |
| 2019 | - | -35.8 mio. | -41.2 mio. | 524 t. | 7 |
| 2018 | - | -18.6 mio. | -25.1 mio. | -6.5 mio. | 10 |
Official annual report
Keep an eye on ACESION PHARMA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ACESION PHARMA ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -25,157,000.
As of June 1, 2022, Anders Gaarsdal Holst is registered as adm. dir. of ACESION PHARMA ApS.
As of June 1, 2022, Torgeir Vaage has stepped down as director of ACESION PHARMA ApS.
As of January 6, 2022, Ann Mills-Duggan has left the board of directors of ACESION PHARMA ApS.
About ACESION PHARMA ApS
ACESION PHARMA ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2011. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Anders Gaarsdal Holst. The board consists of Jørgen Søberg Petersen (chair), Benjamin Bruno Thorner, Nik Economopoulos and Timothy Michael Shannon. The company's owners include Novo Holdings A/S, Canaan XII L.P. and Alpha Wave Ventures II, LP. The company has 14 employees (2018). In 2025, the company reported a net result of DKK -59,597,000 compared with DKK -43,033,000 the year before. Equity in the 2025 report amounted to DKK 276,067,000.